<DOC>
	<DOCNO>NCT01672801</DOCNO>
	<brief_summary>The main purpose study test effectiveness nimodipine prevent luteinizing hormone ( LH ) surge woman undergo ovulation induction clomiphene citrate . It important prevent premature LH surge control ovarian stimulation allow adequate recruitment follicle , proper maturation dominant follicle ovulation , effectively time insemination semen allow fertilization mature egg occur . The investigator also conduct study determine medication side effect profile ( include lightheadedness dizziness low blood pressure rapid heart rate , headache , nausea ) , patient treatment compliance , clinical pregnancy ( positive pregnancy test ultrasound evidence fetal heart rate ) . Finally , LH follicle stimulate hormone ( FSH ) serum level measure determine effect nimodipine hormone . As calcium channel blocker , nimodipine show block calcium mediate release gonadotropin release hormone animal preliminary human study . The investigator hypothesize nimodipine , calcium channel blocker , prevent delay LH surge control ovarian stimulation cycle use clomiphene citrate subfertile patient undergo assisted reproduction intrauterine insemination ( IUI ) .</brief_summary>
	<brief_title>Nimodipine Prevent LH Surge During Ovulation Induction : Blinded Placebo-controlled RCT</brief_title>
	<detailed_description>After enrollment , subject randomize Placebo Comparator Active Comparator . All subject receive Clomid 100 mg 5 day purpose ovarian follicle recruitment . Intervention initiate ovarian follicle maturation document ( ≥1 ovarian follicle size ≥ 17mm ) absence premature LH surge confirm - classify intervention day 0 . Subjects receive assign comparator ( Placebo Active ) accord schedule : - Intervention Day 0 - noon / afternoon / bedtime ( 3 dos ) - Intervention Day 1 - morning / noon / afternoon / bedtime ( 4 dos ) - Intervention Day 2 - morning ( 1 dose ) Serum hormone level ultrasound examination occur day 0,1 2 subject .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Nimodipine</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Age 2540 year time enrollment Both ovary intact history ultrasound assessment Early follicular phase ( day 24 ) serum FSH level &lt; 20 mIU/mL Diagnosis subfertility recommend treatment COH IUI Providing write informed consent English Body mass index ( BMI ) &gt; 38 kg/m2 Early follicular phase ( day 24 ) serum FSH level ≥20 mIU/mL History overstimulated cycle define &gt; 3 mature follicle ≥17 mm Abnormal uterine cavity and/or tubal disease ( evidence sonohysterogram hysterosalpingogram ) Diagnosis infertility clear indication invitro fertilization , bilateral tubal occlusion Severe male factor infertility : Total Motile Sperm Count &lt; 2x106 post washing ( sperm deem inadequate IUI preparation ) Any ovarian abdominal abnormality may interfere adequate TV ultrasound evaluation Absence one ovaries Any contraindication pregnant carry pregnancy term Unexplained gynecological bleeding Any medical condition would jeopardize patient integrity data obtain include : Prior reaction side effect previous calcium channel blocker use Any medical condition may interfere absorption , distribution , metabolism excretion nimodipine hepatic disease , hypertension , seizure , concurrent infection , depression , reflux ( see # 12 ) . Mental health status result cognitive emotional impairment would preclude study participation The concurrent use follow drug : [ These medication show effect availability medication worsen hypotension symptom ] Antihypertensives ( eg . ACE inhibitor , alphaadrenergic block agent , methyldopa , betablockers , diuretic , PDE5 inhibitor , calcium antagonist ) Antiepileptics ( eg . phenobarbital , phenytoin , carbamazepine valproic acid ) Macrolide antibiotic ( eg , erythromycin ) Azole antimycotic ( eg , ketoconazole ) HIV protease inhibitor ( eg , ritonavir ) Antidepressants ( eg , nefazodone fluoxetine ) Cimetidine Patient unable communicate adequately investigator comply requirement study Unwillingness give write informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>